Life Sciences

  • July 14, 2026

    Patent Eligibility Bill Divides Senators Over Health Costs

    Several U.S. senators expressed strong support at a hearing Tuesday for a bill aimed at expanding which inventions are eligible for patents, while others appeared to have reservations about the potential effect of the proposed changes on healthcare costs.

  • July 14, 2026

    Bayer Defends Fees For Seed Tech With Expired Patents

    Bayer asked a Missouri federal judge to dismiss a sweeping antitrust proposed class action, arguing that the independent seed company suing it, in a complaint that also includes breach of contract allegations, is contesting perfectly legal licensing fees charged for corn technology, even after the last patents expired.

  • July 14, 2026

    Judge Says Vanda-FDA Appointments Fight Likely Ripe

    A D.C. federal judge said he likely had jurisdiction to hear Vanda Pharmaceuticals' latest challenge to the Food and Drug Administration's structure for reviewing new drug applications, but wondered if a recent U.S. Supreme Court decision might doom the company's challenge on the merits.

  • July 14, 2026

    Medical Device Co. Settles FCA Claims

    A company that sells compression devices to reduce swelling in patients with certain medical conditions will pay $551,000 to settle allegations that it obtained Medicare reimbursement with falsified medical records, the U.S. attorney's office in Massachusetts announced Tuesday.

  • July 14, 2026

    CVS Caremark Settles Out Of FTC Suit Over Insulin Pricing

    The Federal Trade Commission reached a settlement on Tuesday with CVS Caremark that includes a number of changes to its business practices, the second deal in a case accusing the country's largest pharmacy benefit managers of inflating insulin prices through unfair rebate schemes.

  • July 14, 2026

    Google Is Wrong, 'Settled Expectations' Is Legal, Justices Told

    Software company VirtaMove has argued that the U.S. Supreme Court should ignore Google's challenge to the U.S. Patent and Trademark Office's policy of using the age of patents as a reason to not review them, saying Google's fight is based on a false foundation.

  • July 14, 2026

    Cayman Judge Orders VC Apple Tree's Management Removed

    A Cayman Islands judge has appointed independent officers to direct Apple Tree Life Sciences Inc., handing a win to a fund tied to a longtime Apple Tree investor that has sought to oust the biotechnology investment company's management as part of a protracted feud.

  • July 14, 2026

    Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says

    Conservative advocacy organization Eagle Forum Education & Legal Defense Fund on Tuesday urged the Federal Circuit to reject a proposal to shift a multibillion-dollar patent infringement case over the COVID-19 vaccine that is targeting Moderna to the federal government, saying doing so would reduce the crucial economic incentives that power innovation in the pharmaceutical industry.

  • July 14, 2026

    Top Enviro Policy Developments From The First Half Of 2026

    The first half of 2026 saw the repeal of a key rule underlying federal climate regulation, the rollback of pollution limits on industrial chemicals like ethylene oxide, and a blanket exemption from species protections for Gulf oil drillers. Here, Law360 takes a look at the top five developments in environmental policy and regulation so far this year.

  • July 14, 2026

    Goodwin Adds Life Sciences Veteran For San Diego Relaunch

    Goodwin Procter LLP announced on Tuesday that it had hired a veteran life sciences attorney to co-chair its new San Diego office, which is slated to open later this summer.

  • July 14, 2026

    AI Drug Discovery Biz Valued At $3.8B After Series C Round

    Artificial intelligence-based drug discovery company Chai Discovery on Tuesday revealed that it reached a $3.8 billion valuation after closing its latest funding round with $400 million in tow.

  • July 14, 2026

    BakerHostetler Flips Holland & Knight's Antitrust Co-Lead

    An attorney with nearly 25 years of experience in commercial and antitrust litigation has moved his practice to BakerHostetler's Philadelphia office after five years with Holland & Knight LLP.

  • July 14, 2026

    States Will Get $18M From 23andMe Ch. 11 For Data Breach

    A week after a bankruptcy court approved a $46.75 million settlement between the DNA testing company 23andMe and data breach claimants, a coalition of more than 40 states announced Tuesday that they would share in an additional $18 million to resolve claims of unreasonable security practices.

  • July 14, 2026

    Pharma Cos. Clash In Del. Chancery Over Dental Drug License

    Ventis Pharma Inc. has sued Balanced Pharma Inc. in the Delaware Chancery Court, accusing its licensee of failing to make commercially reasonable efforts to develop and market a licensed dental anesthetic product and seeking a declaration that the companies' exclusive licensing agreement has been terminated.

  • July 13, 2026

    Albertsons, Safeway Face Trial Over Wash.'s Opioid Epidemic

    Albertsons and Safeway ignored signs of problematic opioid prescriptions in Washington for years, an attorney for the state told a Seattle judge Monday during opening statements in a bench trial over allegations that the pharmacy chains failed to prevent the diversion of opioids that fueled the state's long-running overdose crisis.

  • July 13, 2026

    2nd Circ. Says Tylenol Maker Must Face Autism, ADHD Suits

    The Second Circuit said Monday that a lower court had wrongly excluded plaintiffs experts from testifying about an alleged relationship between using Tylenol during pregnancy and autism spectrum disorder and attention-deficit/hyperactivity disorder, although the panel cautioned that the decision was not political or scientific.

  • July 13, 2026

    FTC Secures $12M Settlement Over Edwards-JC Medical Deal

    California-based Edwards Lifesciences and Singapore's Genesis Medtech agreed to pay a combined $12 million to settle claims from the Federal Trade Commission that Edwards attempted to evade the Hart-Scott-Rodino notification and waiting period when it acquired medical device maker JC Medical from Genesis in 2024.

  • July 13, 2026

    CVS Toddler Wipes Mislabeled As Hypoallergenic, Suit Says

    CVS customers hit the pharmacy retail giant with a proposed false advertising class action in California federal court alleging that its "Ultra-Soft Toddler Cleansing Wipes" are deceptively labeled as being hypoallergenic, since they are formulated with added fragrance, a cosmetic allergen that serves no functional skin care purpose.

  • July 13, 2026

    7th Circ. Revives Teva Suit Over Eli Lilly Generic Drug Block

    The Seventh Circuit on Monday revived a breach-of-contract lawsuit against Eli Lilly, ruling that an earlier legal settlement under which Eli Lilly agreed not to block the approval and marketing of Teva Pharmaceuticals' generic version of its osteoporosis drug Forteo didn't necessarily expire when the underlying patents did.

  • July 13, 2026

    23andMe Bankruptcy Plan Bars Data Breach Suit In Calif.

    A Missouri bankruptcy judge has told attorneys representing California the state can no longer press its data breach lawsuit against the reorganized 23andMe, finding the state court action is barred by the company's confirmed Chapter 11 plan.

  • July 13, 2026

    Assertio Beats Investor Suit Over Drug, Merger Claims

    An Illinois federal judge Friday dismissed a proposed investor class action claiming Assertio misled shareholders about threats to sales of its arthritis drug Indocin, saying the company's public filings explicitly and repeatedly warned that the drug lacked patent protection and faced imminent generic competition at any time.

  • July 13, 2026

    Families Cite Geofence Ruling In Newborn Blood Testing Case

    A group of parents suing the state of Michigan over the way newborn blood samples are collected and stored has asked a federal judge to revive its claims by citing recently decided U.S. Supreme Court precedent over the use of bulk cellphone data by police.

  • July 13, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week handled disputes involving corporate control, post-closing competition, executive departures, arbitration awards and shareholder litigation.

  • July 13, 2026

    Health Org. Can't Halt FTC Texas Suit Over Trans Youth Care

    A D.C. federal court declined to bar the Federal Trade Commission from pursuing a consumer protection suit in Texas against the World Professional Association for Transgender Health, finding WPATH failed to show those proceedings threatened the court's injunction of a related investigation by the FTC.

  • July 10, 2026

    Thermo Fisher Looks To Block Former Exec's Move To Fortrea

    Thermo Fisher is asking a Delaware court to prevent a former executive's move to a direct competitor following its $8.875 billion acquisition of Clario in March 2026, saying the new leadership role is in violation of contractual obligations negotiated as part of the acquisition.

Expert Analysis

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.